Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

A patient from Mali with Actinomadura bangladeshensis-induced foot mycetoma: A diagnostic challenge.

Bérot V, Ousser AF, Sougakoff W, Lecso G, Monsel G, Caumes E.

Travel Med Infect Dis. 2019 Aug 1:101452. doi: 10.1016/j.tmaid.2019.07.008. [Epub ahead of print] No abstract available.

PMID:
31377463
2.

Erwinia billingiae as Unusual Cause of Septic Arthritis, France, 2017.

Bonnet I, Bozzi B, Fourniols E, Mitrovic S, Soulier-Escrihuela O, Brossier F, Sougakoff W, Robert J, Jauréguiberry S, Aubry A; Pitié-Salpêtrière Infection Ostéo-articulaire group.

Emerg Infect Dis. 2019 Aug;25(8):1587-1589. doi: 10.3201/eid2508.181073.

3.

First genetic characterization of multi-drug resistant Mycobacterium tuberculosis isolates from Algeria.

Bouziane F, Allem R, Sebahia M, Kumanski S, Mougari F, Sougakoff W, Raskine L, Yala D, Cambau E; CNR-MyRMA.

J Glob Antimicrob Resist. 2019 May 14. pii: S2213-7165(19)30120-1. doi: 10.1016/j.jgar.2019.05.010. [Epub ahead of print]

PMID:
31100498
4.

Poor Performance of Rapid Molecular Tests to Define Eligibility for the Shortcourse Multidrug-resistant Tuberculosis Regimen.

Guglielmetti L, Sougakoff W, Maitre T, Brossier F, Jarlier V, Robert J, Veziris N, Aubry A; French National Reference Center of Mycobacteria.

Clin Infect Dis. 2019 Apr 8;68(8):1410-1411. doi: 10.1093/cid/ciy808.

PMID:
30239638
5.

Unexpected Genomic and Phenotypic Diversity of Mycobacterium africanum Lineage 5 Affects Drug Resistance, Protein Secretion, and Immunogenicity.

Ates LS, Dippenaar A, Sayes F, Pawlik A, Bouchier C, Ma L, Warren RM, Sougakoff W, Majlessi L, van Heijst JWJ, Brossier F, Brosch R.

Genome Biol Evol. 2018 Aug 1;10(8):1858-1874. doi: 10.1093/gbe/evy145.

6.

Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors.

Sayes F, Blanc C, Ates LS, Deboosere N, Orgeur M, Le Chevalier F, Gröschel MI, Frigui W, Song OR, Lo-Man R, Brossier F, Sougakoff W, Bottai D, Brodin P, Charneau P, Brosch R, Majlessi L.

Cell Rep. 2018 Apr 24;23(4):1072-1084. doi: 10.1016/j.celrep.2018.03.125.

7.

Estimation of pyrazinamidase activity using a cell-free In vitro synthesis of pnca and its association with pyrazinamide susceptibility in Mycobacterium tuberculosis.

Rueda D, Bernard C, Gandy L, Capton E, Boudjelloul R, Brossier F, Veziris N, Zimic M, Sougakoff W.

Int J Mycobacteriol. 2018 Jan-Mar;7(1):16-25. doi: 10.4103/ijmy.ijmy_187_17.

8.

Risk factors for extensive drug resistance in multidrug-resistant tuberculosis cases: a case-case study.

Guglielmetti L, Veziris N, Aubry A, Brossier F, Bernard C, Sougakoff W, Jarlier V, Robert J.

Int J Tuberc Lung Dis. 2018 Jan 1;22(1):54-59. doi: 10.5588/ijtld.17.0387.

PMID:
29297426
9.

Neither genotyping nor contact tracing allow correct understanding of multidrug-resistant tuberculosis transmission.

Fournier A, Bernard C, Sougakoff W, Quelet S, Antoun F, Charlois-Ou C, Dormant I, Dufour MO, Hocine N, Jarlier V, Veziris N.

Eur Respir J. 2017 Sep 11;50(3). pii: 1700891. doi: 10.1183/13993003.00891-2017. Print 2017 Sep. No abstract available.

10.

Extra-corporeal membrane oxygenation-associated infections: implication of extra-intestinal pathogenic Escherichia coli clones.

Messika J, Clermont O, Landraud L, Schmidt M, Aubry A, Sougakoff W, Fernandes R, Combes A, Denamur E, Ricard JD.

J Med Microbiol. 2017 Aug;66(8):1189-1195. doi: 10.1099/jmm.0.000554. Epub 2017 Aug 4.

PMID:
28771132
11.

Investigation of pre-XDR Beijing Mycobacterium tuberculosis transmission to a healthcare worker in France, 2016.

Appelgren A, Morquin D, Dufour S, Le Moing V, Reynes J, Lotthé A, Parer S, Corbeau C, Aubry A, Sougakoff W, Solassol J, Bonzon L, Dumont Y, Godreuil S.

J Hosp Infect. 2017 Dec;97(4):414-417. doi: 10.1016/j.jhin.2017.06.030. Epub 2017 Jun 30.

PMID:
28669673
12.

Molecular detection methods of resistance to antituberculosis drugs in Mycobacterium tuberculosis.

Brossier F, Sougakoff W; French National Reference Center for Mycobacteria(b).

Med Mal Infect. 2017 Sep;47(5):340-348. doi: 10.1016/j.medmal.2017.04.008. Epub 2017 Jun 17.

PMID:
28629614
13.

Evaluation of the new GenoType NTM-DR kit for the molecular detection of antimicrobial resistance in non-tuberculous mycobacteria.

Mougari F, Loiseau J, Veziris N, Bernard C, Bercot B, Sougakoff W, Jarlier V, Raskine L, Cambau E; French National Reference Center for Mycobacteria.

J Antimicrob Chemother. 2017 Jun 1;72(6):1669-1677. doi: 10.1093/jac/dkx021.

PMID:
28333340
14.

Rapid emergence of Mycobacterium tuberculosis bedaquiline resistance: lessons to avoid repeating past errors.

Veziris N, Bernard C, Guglielmetti L, Le Du D, Marigot-Outtandy D, Jaspard M, Caumes E, Lerat I, Rioux C, Yazdanpanah Y, Tiotiu A, Lemaitre N, Brossier F, Jarlier V, Robert J, Sougakoff W, Aubry A; CNR MyRMA and the Tuberculosis Consilium of the CNR MyRMA; CNR MyRMA and Tuberculosis Consilium of the CNR MyRMA.

Eur Respir J. 2017 Mar 22;49(3). pii: 1601719. doi: 10.1183/13993003.01719-2016. Print 2017 Mar. No abstract available.

15.

Diversity and functionality of plasmid-borne VagCD toxin-antitoxin systems of Klebsiella pneumoniae.

Duprilot M, Decre D, Genel N, Drieux L, Sougakoff W, Arlet G.

J Antimicrob Chemother. 2017 May 1;72(5):1320-1326. doi: 10.1093/jac/dkw569.

PMID:
28119479
16.

Molecular Investigation of Resistance to Second-Line Injectable Drugs in Multidrug-Resistant Clinical Isolates of Mycobacterium tuberculosis in France.

Brossier F, Pham A, Bernard C, Aubry A, Jarlier V, Veziris N, Sougakoff W; CNR-MyRMA.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01299-16. doi: 10.1128/AAC.01299-16. Print 2017 Feb.

17.

The in vitro mechanisms of isoniazid and ethionamide resistance poorly reflect those in vivo in Mycobacterium tuberculosis.

Brossier F, Cambau E, Tessier E, Jarlier V, Sougakoff W.

Tuberculosis (Edinb). 2016 Dec;101:144-145. doi: 10.1016/j.tube.2016.09.028. Epub 2016 Sep 29. No abstract available.

PMID:
27865384
18.

Comparative study of enzymatic activities of new KatG mutants from low- and high-level isoniazid-resistant clinical isolates of Mycobacterium tuberculosis.

Brossier F, Boudinet M, Jarlier V, Petrella S, Sougakoff W.

Tuberculosis (Edinb). 2016 Sep;100:15-24. doi: 10.1016/j.tube.2016.06.002. Epub 2016 Jun 16.

19.

Description of compensatory gyrA mutations restoring fluoroquinolone susceptibility in Mycobacterium tuberculosis.

Pantel A, Petrella S, Veziris N, Matrat S, Bouige A, Ferrand H, Sougakoff W, Mayer C, Aubry A.

J Antimicrob Chemother. 2016 Sep;71(9):2428-31. doi: 10.1093/jac/dkw169. Epub 2016 May 27.

PMID:
27234461
20.

Performance of the New Version (v2.0) of the GenoType MTBDRsl Test for Detection of Resistance to Second-Line Drugs in Multidrug-Resistant Mycobacterium tuberculosis Complex Strains.

Brossier F, Guindo D, Pham A, Reibel F, Sougakoff W, Veziris N, Aubry A.

J Clin Microbiol. 2016 Jun;54(6):1573-1580. doi: 10.1128/JCM.00051-16. Epub 2016 Apr 6.

21.

XDR-tuberculosis in France: Community transmission due to non-compliance with isolation precautions.

Lafeuille E, Veziris N, Sougakoff W, Roure F, Le Dû D, Dournon N, Caumes E, Jarlier V, Aubry A, Robert J, Bernard C.

Med Mal Infect. 2016 Feb;46(1):52-5. doi: 10.1016/j.medmal.2015.12.008. Epub 2016 Jan 19. No abstract available.

PMID:
26809373
22.

Assessing primary and secondary resistance to clarithromycin and amikacin in infections due to Mycobacterium avium complex.

Renvoisé A, Brossier F, Galati E, Veziris N, Sougakoff W, Aubry A, Robert J, Cambau E, Jarlier V, Bernard C.

Antimicrob Agents Chemother. 2015 Nov;59(11):7153-5. doi: 10.1128/AAC.01027-15. Epub 2015 Aug 31. No abstract available.

23.

Characterization of a Clone of Mycobacterium tuberculosis Clinical Isolates with Mutations in KatG (A110V), EthA (Q269STOP), and the inhA Promoter (-15C→T).

Brossier F, Sola C, Bernard C, Jarlier V, Veziris N, Sougakoff W.

J Clin Microbiol. 2015 Sep;53(9):3104. doi: 10.1128/JCM.01537-15. Epub 2015 Jul 8. No abstract available.

24.

Molecular Analysis of the embCAB Locus and embR Gene Involved in Ethambutol Resistance in Clinical Isolates of Mycobacterium tuberculosis in France.

Brossier F, Sougakoff W, Bernard C, Petrou M, Adeyema K, Pham A, Amy de la Breteque D, Vallet M, Jarlier V, Sola C, Veziris N.

Antimicrob Agents Chemother. 2015 Aug;59(8):4800-8. doi: 10.1128/AAC.00150-15. Epub 2015 Jun 1.

25.

Detection of OXA-48-like carbapenemase genes by the Xpert® Carba-R test: room for improvement.

Lafeuille E, Laouira S, Sougakoff W, Soulier-Escrihuela O, Leconte J, Garrec H, Tourret J, Jarlier V, Robert J.

Int J Antimicrob Agents. 2015 Apr;45(4):441-2. doi: 10.1016/j.ijantimicag.2014.12.009. Epub 2014 Dec 31. No abstract available.

PMID:
25601530
26.

Molecular diagnosis of fluoroquinolone resistance in Mycobacterium tuberculosis.

Bernard C, Veziris N, Brossier F, Sougakoff W, Jarlier V, Robert J, Aubry A.

Antimicrob Agents Chemother. 2015 Mar;59(3):1519-24. doi: 10.1128/AAC.04058-14. Epub 2014 Dec 22.

28.

Aedesin: structure and antimicrobial activity against multidrug resistant bacterial strains.

Godreuil S, Leban N, Padilla A, Hamel R, Luplertlop N, Chauffour A, Vittecoq M, Hoh F, Thomas F, Sougakoff W, Lionne C, Yssel H, Missé D.

PLoS One. 2014 Aug 27;9(8):e105441. doi: 10.1371/journal.pone.0105441. eCollection 2014.

29.

First Whole-Genome Sequence of a Clinical Isolate of Multidrug-Resistant Mycobacterium bovis BCG.

Renvoisé A, Pang S, Bernard C, Brossier F, Veziris N, Capton E, Jarlier V, Sougakoff W.

Genome Announc. 2014 Jul 10;2(4). pii: e00611-14. doi: 10.1128/genomeA.00611-14.

30.

First evaluation of drug-resistant Mycobacterium tuberculosis clinical isolates from Congo revealed misdetection of fluoroquinolone resistance by line probe assay due to a double substitution T80A-A90G in GyrA.

Aubry A, Sougakoff W, Bodzongo P, Delcroix G, Armand S, Millot G, Jarlier V, Courcol R, Lemaître N.

PLoS One. 2014 Apr 17;9(4):e95083. doi: 10.1371/journal.pone.0095083. eCollection 2014. Erratum in: PLoS One. 2014;9(11):e113219.

31.

Concomitant multidrug-resistant pulmonary tuberculosis and susceptible tuberculous meningitis.

Bernard C, Brossier F, Fréchet-Jachym M, Morand PC, Coignard S, Aslangul E, Aubry A, Jarlier V, Sougakoff W, Veziris N.

Emerg Infect Dis. 2014 Mar;20(3):506-7. doi: 10.3201/eid2003.131205. No abstract available.

32.

Whole-Genome Sequence of Mycobacterium abscessus Clinical Strain V06705.

Pang S, Renvoisé A, Perret C, Guinier M, Chelghoum N, Brossier F, Capton E, Jarlier V, Sougakoff W.

Genome Announc. 2013 Sep 5;1(5). pii: e00690-13. doi: 10.1128/genomeA.00690-13.

33.

A surge of MDR and XDR tuberculosis in France among patients born in the Former Soviet Union.

Bernard C, Brossier F, Sougakoff W, Veziris N, Frechet-Jachym M, Metivier N, Renvoisé A, Robert J, Jarlier V; MDR-TB Management group of the NRC.

Euro Surveill. 2013 Aug 15;18(33):20555. Erratum in: Euro Surveill. 2013;18(36). pii: 20576.

34.

Broad-range PCR: past, present, or future of bacteriology?

Renvoisé A, Brossier F, Sougakoff W, Jarlier V, Aubry A.

Med Mal Infect. 2013 Aug;43(8):322-30. doi: 10.1016/j.medmal.2013.06.003. Epub 2013 Jul 19. Review.

PMID:
23876208
35.

Complete nucleotide sequence of the large conjugative pTC2 multireplicon plasmid encoding the VIM-1 metallo-β-lactamase.

Drieux L, Decré D, Frangeul L, Arlet G, Jarlier V, Sougakoff W.

J Antimicrob Chemother. 2013 Jan;68(1):97-100. doi: 10.1093/jac/dks367. Epub 2012 Sep 25.

PMID:
23011287
36.

Impact of a 14-year screening programme on tuberculosis transmission among the homeless in Paris.

Bernard C, Sougakoff W, Fournier A, Larnaudie S, Antoun F, Robert J, Brossier F, Truffot-Pernot C, Jarlier V, Veziris N.

Int J Tuberc Lung Dis. 2012 May;16(5):649-55. doi: 10.5588/ijtld.11.0241. Epub 2012 Mar 8.

PMID:
22410620
37.

New mutations in the mycobacterial ATP synthase: new insights into the binding of the diarylquinoline TMC207 to the ATP synthase C-ring structure.

Segala E, Sougakoff W, Nevejans-Chauffour A, Jarlier V, Petrella S.

Antimicrob Agents Chemother. 2012 May;56(5):2326-34. doi: 10.1128/AAC.06154-11. Epub 2012 Feb 21.

38.

Matrix-assisted laser desorption ionization-time of flight mass spectrometry-based single nucleotide polymorphism genotyping assay using iPLEX gold technology for identification of Mycobacterium tuberculosis complex species and lineages.

Bouakaze C, Keyser C, Gonzalez A, Sougakoff W, Veziris N, Dabernat H, Jaulhac B, Ludes B.

J Clin Microbiol. 2011 Sep;49(9):3292-9. doi: 10.1128/JCM.00744-11. Epub 2011 Jul 6.

39.

Molecular epidemiology of multidrug-resistant strains of Mycobacterium tuberculosis.

Sougakoff W.

Clin Microbiol Infect. 2011 Jun;17(6):800-5. doi: 10.1111/j.1469-0691.2011.03577.x. Review.

40.

Accumulation of carbapenemase-producing Gram-negative bacteria in a single patient linked to the acquisition of multiple carbapenemase producers and to the in vivo transfer of a plasmid encoding VIM-1.

Drieux L, Bourgeois-Nicolaos N, Cremniter J, Lawrence C, Jarlier V, Doucet-Populaire F, Sougakoff W.

Int J Antimicrob Agents. 2011 Aug;38(2):179-80. doi: 10.1016/j.ijantimicag.2011.03.017. Epub 2011 May 13. No abstract available.

PMID:
21570257
41.

Crystal structure of the pyrazinamidase of Mycobacterium tuberculosis: insights into natural and acquired resistance to pyrazinamide.

Petrella S, Gelus-Ziental N, Maudry A, Laurans C, Boudjelloul R, Sougakoff W.

PLoS One. 2011 Jan 24;6(1):e15785. doi: 10.1371/journal.pone.0015785.

42.

MmpS4 promotes glycopeptidolipids biosynthesis and export in Mycobacterium smegmatis.

Deshayes C, Bach H, Euphrasie D, Attarian R, Coureuil M, Sougakoff W, Laval F, Av-Gay Y, Daffé M, Etienne G, Reyrat JM.

Mol Microbiol. 2010 Nov;78(4):989-1003. doi: 10.1111/j.1365-2958.2010.07385.x. Epub 2010 Sep 29.

43.

Molecular investigation of resistance to the antituberculous drug ethionamide in multidrug-resistant clinical isolates of Mycobacterium tuberculosis.

Brossier F, Veziris N, Truffot-Pernot C, Jarlier V, Sougakoff W.

Antimicrob Agents Chemother. 2011 Jan;55(1):355-60. doi: 10.1128/AAC.01030-10. Epub 2010 Oct 25.

44.

Detection by GenoType MTBDRsl test of complex mechanisms of resistance to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates.

Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W.

J Clin Microbiol. 2010 May;48(5):1683-9. doi: 10.1128/JCM.01947-09. Epub 2010 Mar 24.

45.

Identification and genotyping of Mycobacterium tuberculosis complex species by use of a SNaPshot Minisequencing-based assay.

Bouakaze C, Keyser C, de Martino SJ, Sougakoff W, Veziris N, Dabernat H, Ludes B.

J Clin Microbiol. 2010 May;48(5):1758-66. doi: 10.1128/JCM.02255-09. Epub 2010 Mar 10.

46.

Two concomitant but unrelated cases of Pasteurella multocida infection, including meningitis secondary to pituitary adenoma microsurgery.

Brossier F, Clemenceau S, Lecso-Bornet M, Jarlier V, Sougakoff W.

Med Mal Infect. 2010 Oct;40(10):590-2. doi: 10.1016/j.medmal.2009.12.003. Epub 2010 Jan 15. No abstract available.

PMID:
20079991
47.

Comment on: Redefining extended-spectrum beta-lactamases: balancing science and clinical need.

Bush K, Jacoby GA, Amicosante G, Bonomo RA, Bradford P, Cornaglia G, Garau J, Giamarellou H, Jarlier V, Martinez-Martinez L, Miriagou V, Palzkill T, Pascual A, Rodriguez-Baño J, Rossolini GM, Sougakoff W, Vatopoulos A.

J Antimicrob Chemother. 2009 Jul;64(1):212-3; author reply 213-5. doi: 10.1093/jac/dkp104. Epub 2009 Mar 24. No abstract available.

PMID:
19318363
48.

Performance of MTBDR plus for detecting high/low levels of Mycobacterium tuberculosis resistance to isoniazid.

Brossier F, Veziris N, Jarlier V, Sougakoff W.

Int J Tuberc Lung Dis. 2009 Feb;13(2):260-5.

PMID:
19146757
49.

Increase in hospital-acquired bloodstream infections caused by extended spectrum beta-lactamase-producing Escherichia coli in a large French teaching hospital.

Drieux L, Brossier F, Duquesnoy O, Aubry A, Robert J, Sougakoff W, Lecso-Bornet M, Jarlier V.

Eur J Clin Microbiol Infect Dis. 2009 May;28(5):491-8. doi: 10.1007/s10096-008-0656-6. Epub 2008 Nov 12.

PMID:
19002728
50.

Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A beta-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France.

Petrella S, Ziental-Gelus N, Mayer C, Renard M, Jarlier V, Sougakoff W.

Antimicrob Agents Chemother. 2008 Oct;52(10):3725-36. doi: 10.1128/AAC.00163-08. Epub 2008 Jul 14.

Supplemental Content

Loading ...
Support Center